{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:47:41Z","timestamp":1794602861490,"version":"4.9.1"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41571-024-00886-y","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T13:01:46Z","timestamp":1712754106000},"page":"468-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Antiangiogenic\u2013immune-checkpoint inhibitor combinations: lessons from phase III clinical trials"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-2636","authenticated-orcid":false,"given":"Hung-Yang","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8453-3485","authenticated-orcid":false,"given":"Kabir A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6015-2570","authenticated-orcid":false,"given":"Robert S.","family":"Kerbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"886_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223\u2013249 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"886_CR2","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1373\/clinchem.2016.267849","volume":"63","author":"IM Blasutig","year":"2017","unstructured":"Blasutig, I. M. et al. The phoenix rises: the rebirth of cancer immunotherapy. Clin. Chem. 63, 1190\u20131195 (2017).","journal-title":"Clin. Chem."},{"key":"886_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/imt-2022-0185","volume":"15","author":"SJ Abi-Aad","year":"2023","unstructured":"Abi-Aad, S. J., Zouein, J., Chartouni, A., Naim, N. & Kourie, H. R. Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy? Immunotherapy 15, 611\u2013618 (2023).","journal-title":"Immunotherapy"},{"key":"886_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24\u201334 (2022).","journal-title":"N. Engl. J. Med."},{"key":"886_CR5","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","volume":"18","author":"NL Syn","year":"2017","unstructured":"Syn, N. L., Teng, M. W. L., Mok, T. S. K. & Soo, R. A. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 18, e731\u2013e741 (2017).","journal-title":"Lancet Oncol."},{"key":"886_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9\u201316 (2018).","journal-title":"Br. J. Cancer"},{"key":"886_CR7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","volume":"24","author":"TN Gide","year":"2018","unstructured":"Gide, T. N., Wilmott, J. S., Scolyer, R. A. & Long, G. V. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin. Cancer Res. 24, 1260\u20131270 (2018).","journal-title":"Clin. Cancer Res."},{"key":"886_CR8","first-page":"9","volume":"8","author":"A Andrews","year":"2015","unstructured":"Andrews, A. Treating with checkpoint inhibitors \u2013 figure $1 million per patient. Am. Health Drug. Benefits 8, 9 (2015).","journal-title":"Am. Health Drug. Benefits"},{"key":"886_CR9","doi-asserted-by":"publisher","first-page":"k793","DOI":"10.1136\/bmj.k793","volume":"360","author":"S Baxi","year":"2018","unstructured":"Baxi, S. et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 360, k793 (2018).","journal-title":"BMJ"},{"key":"886_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"886_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2217\/fon-2018-0607","volume":"15","author":"NA Carreau","year":"2019","unstructured":"Carreau, N. A. & Pavlick, A. C. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. Future Oncol. 15, 349\u2013358 (2019).","journal-title":"Future Oncol."},{"key":"886_CR12","doi-asserted-by":"publisher","first-page":"109881","DOI":"10.1016\/j.intimp.2023.109881","volume":"117","author":"M Nikoo","year":"2023","unstructured":"Nikoo, M. et al. Nivolumab plus ipilimumab combination therapy in cancer: current evidence to date. Int. Immunopharmacol. 117, 109881 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"886_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375\u2013386 (2021).","journal-title":"Lancet"},{"key":"886_CR14","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1002\/jcp.29371","volume":"235","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J. Cell Physiol. 235, 4913\u20134927 (2020).","journal-title":"J. Cell Physiol."},{"key":"886_CR15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buqu\u00e9, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"886_CR16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","volume":"22","author":"Y Cao","year":"2023","unstructured":"Cao, Y., Langer, R. & Ferrara, N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat. Rev. Drug. Discov. 22, 476\u2013495 (2023).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"886_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00281-018-0714-9","volume":"41","author":"EV Schmidt","year":"2019","unstructured":"Schmidt, E. V. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. Semin. Immunopathol. 41, 21\u201330 (2019).","journal-title":"Semin. Immunopathol."},{"key":"886_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","volume":"11","author":"GT Motz","year":"2011","unstructured":"Motz, G. T. & Coukos, G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11, 702\u2013711 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"886_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/cmmi.1564","volume":"9","author":"L Heijmen","year":"2014","unstructured":"Heijmen, L. et al. Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media Mol. imaging 9, 237\u2013245 (2014).","journal-title":"Contrast Media Mol. imaging"},{"key":"886_CR20","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1158\/0008-5472.CAN-05-3295","volume":"66","author":"M Franco","year":"2006","unstructured":"Franco, M. et al. Targeted anti-VEGFR-2 therapy leads to short and long term impairment of vascular function and increases in tumor hypoxia. Cancer Res. 66, 3639\u20133648 (2006).","journal-title":"Cancer Res."},{"key":"886_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.canlet.2020.05.011","volume":"487","author":"WH Chang","year":"2020","unstructured":"Chang, W. H. & Lai, A. G. The hypoxic tumour microenvironment: a safe haven for immunosuppressive cells and a therapeutic barrier to overcome. Cancer Lett. 487, 34\u201344 (2020).","journal-title":"Cancer Lett."},{"key":"886_CR22","doi-asserted-by":"publisher","first-page":"100787","DOI":"10.1016\/j.drup.2021.100787","volume":"59","author":"J Kopecka","year":"2021","unstructured":"Kopecka, J. et al. Hypoxia as a driver of resistance to immunotherapy. Drug. Resist. Updat. 59, 100787 (2021).","journal-title":"Drug. Resist. Updat."},{"key":"886_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","volume":"40","author":"B Wang","year":"2021","unstructured":"Wang, B. et al. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J. Exp. Clin. Cancer Res. 40, 24 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"886_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with antiangiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15, 310\u2013324 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"886_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325\u2013340 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"886_CR26","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096\u20131103 (1996).","journal-title":"Nat. Med."},{"key":"886_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162\u2013174 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"886_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron, T. et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T-cells in tumors. J. Exp. Med. 212, 139\u2013148 (2015).","journal-title":"J. Exp. Med."},{"key":"886_CR29","doi-asserted-by":"publisher","first-page":"eaay0555","DOI":"10.1126\/sciimmunol.aay0555","volume":"4","author":"CG Kim","year":"2019","unstructured":"Kim, C. G. et al. VEGF-A drives TOX-dependent T-cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Sci. Immunol. 4, eaay0555 (2019).","journal-title":"Sci. Immunol."},{"key":"886_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"ZR Huinen","year":"2021","unstructured":"Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P. & Griffioen, A. W. Anti-angiogenic agents \u2013 overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat. Rev. Clin. Oncol. 18, 527\u2013540 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"886_CR31","doi-asserted-by":"publisher","first-page":"eabm6388","DOI":"10.1126\/sciimmunol.abm6388","volume":"7","author":"EJM Huijbers","year":"2022","unstructured":"Huijbers, E. J. M. et al. Tumors resurrect an embryonic vascular program to escape immunity. Sci. Immunol. 7, eabm6388 (2022).","journal-title":"Sci. Immunol."},{"key":"886_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607\u2013615 (2014).","journal-title":"Nat. Med."},{"key":"886_CR33","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen, E. et al. Combined antiangiogenic and anti\u2013PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. 9, eaak9679 (2017).","journal-title":"Sci. Transl. Med."},{"key":"886_CR34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nm0603-685","volume":"9","author":"RK Jain","year":"2003","unstructured":"Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685\u2013693 (2003).","journal-title":"Nat. Med."},{"key":"886_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.gde.2004.12.005","volume":"15","author":"P Baluk","year":"2005","unstructured":"Baluk, P., Hashizume, H. & McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15, 102\u2013111 (2005).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"886_CR36","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987\u2013989 (2001).","journal-title":"Nat. Med."},{"key":"886_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41571-021-00539-4","volume":"18","author":"DC Singleton","year":"2021","unstructured":"Singleton, D. C., Macann, A. & Wilson, W. R. Therapeutic targeting of the hypoxic tumour microenvironment. Nat. Rev. Clin. Oncol. 18, 751\u2013772 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"886_CR38","doi-asserted-by":"publisher","first-page":"15101","DOI":"10.1073\/pnas.1213353109","volume":"109","author":"T Stylianopoulos","year":"2012","unstructured":"Stylianopoulos, T. et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc. Natl Acad. Sci. USA 109, 15101\u201315108 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"886_CR39","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","volume":"91","author":"S Goel","year":"2011","unstructured":"Goel, S. et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91, 1071\u20131121 (2011).","journal-title":"Physiol. Rev."},{"key":"886_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/s-0038-1673621","volume":"38","author":"YY Lin","year":"2018","unstructured":"Lin, Y. Y. et al. Immunomodulatory effects of current targeted therapies on hepatocellular carcinoma: implication for the future of immunotherapy. Semin. Liver Dis. 38, 379\u2013388 (2018).","journal-title":"Semin. Liver Dis."},{"key":"886_CR41","first-page":"3","volume":"367","author":"MS Wietecha","year":"2013","unstructured":"Wietecha, M. S., Cerny, W. L. & DiPietro, L. A. Mechanisms of vessel regression: toward an understanding of the resolution of angiogenesis. Curr. Top. Microbiol. Immunol. 367, 3\u201332 (2013).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"886_CR42","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/jnci\/djac051","volume":"114","author":"H Kikuchi","year":"2022","unstructured":"Kikuchi, H. et al. Increased CD8+ T-cell infiltration and efficacy for multikinase inhibitors after PD-1 blockade in hepatocellular carcinoma. J. Natl Cancer Inst. 114, 1301\u20131305 (2022).","journal-title":"J. Natl Cancer Inst."},{"key":"886_CR43","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1158\/1078-0432.CCR-07-0374","volume":"13","author":"EA Manning","year":"2007","unstructured":"Manning, E. A. et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 13, 3951\u20133959 (2007).","journal-title":"Clin. Cancer Res."},{"key":"886_CR44","doi-asserted-by":"publisher","first-page":"eabd1616","DOI":"10.1126\/scitranslmed.abd1616","volume":"13","author":"A Martinez-Usatorre","year":"2021","unstructured":"Martinez-Usatorre, A. et al. Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Sci. Transl. Med. 13, eabd1616 (2021).","journal-title":"Sci. Transl. Med."},{"key":"886_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01658-9","volume":"25","author":"E Hoffmann","year":"2023","unstructured":"Hoffmann, E. et al. Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy. Breast Cancer Res. 25, 56 (2023).","journal-title":"Breast Cancer Res."},{"key":"886_CR46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/0008-5472.CAN-11-2464","volume":"72","author":"AG Sorensen","year":"2012","unstructured":"Sorensen, A. G. et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 72, 402\u2013407 (2012).","journal-title":"Cancer Res."},{"key":"886_CR47","first-page":"553","volume":"6","author":"F Winkler","year":"2004","unstructured":"Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553\u2013563 (2004).","journal-title":"Cancer Cell"},{"key":"886_CR48","doi-asserted-by":"publisher","first-page":"19059","DOI":"10.1073\/pnas.1318022110","volume":"110","author":"TT Batchelor","year":"2013","unstructured":"Batchelor, T. T. et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc. Natl Acad. Sci. USA 110, 19059\u201319064 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"886_CR49","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s12276-023-00939-9","volume":"55","author":"E Lee","year":"2023","unstructured":"Lee, E. et al. An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone. Exp. Mol. Med. 55, 470\u2013484 (2023).","journal-title":"Exp. Mol. Med."},{"key":"886_CR50","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708253","volume":"13","author":"KA Khan","year":"2021","unstructured":"Khan, K. A., Wu, F. T., Cruz-Munoz, W. & Kerbel, R. S. Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. EMBO Mol. Med. 13, e08253 (2021).","journal-title":"EMBO Mol. Med."},{"key":"886_CR51","doi-asserted-by":"publisher","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","volume":"9","author":"M Schmittnaegel","year":"2017","unstructured":"Schmittnaegel, M. et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl. Med. 9, eaak9670 (2017).","journal-title":"Sci. Transl. Med."},{"key":"886_CR52","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/2159-8290.CD-20-0122","volume":"11","author":"N Gengenbacher","year":"2021","unstructured":"Gengenbacher, N. et al. Timed Ang2-targeted therapy identifies the angiopoietin\u2013tie pathway as key regulator of fatal lymphogenous metastasis. Cancer Discov. 11, 424\u2013445 (2021).","journal-title":"Cancer Discov."},{"key":"886_CR53","doi-asserted-by":"publisher","first-page":"eaau6732","DOI":"10.1126\/sciadv.aau6732","volume":"5","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration. Sci. Adv. 5, eaau6732 (2019).","journal-title":"Sci. Adv."},{"key":"886_CR54","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","volume":"83","author":"HR Park","year":"2023","unstructured":"Park, H. R. et al. Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma. Cancer Res. 83, 1968\u20131983 (2023).","journal-title":"Cancer Res."},{"key":"886_CR55","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine 62, 102106 (2023).","journal-title":"EClinicalMedicine"},{"key":"886_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39076-8","volume":"13","author":"N Tzuri","year":"2023","unstructured":"Tzuri, N. et al. Developing a dual VEGF\/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy. Sci. Rep. 13, 11923 (2023).","journal-title":"Sci. Rep."},{"key":"886_CR57","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/08923973.2022.2131571","volume":"45","author":"A Hassanzadeh Eskafi","year":"2023","unstructured":"Hassanzadeh Eskafi, A. et al. Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1\/VEGF nanobody in inhibition of angiogenesis. Immunopharmacol. Immunotoxicol. 45, 197\u2013202 (2023).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"886_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-019-0706-y","volume":"13","author":"X Lai","year":"2019","unstructured":"Lai, X. & Friedman, A. How to schedule VEGF and PD-1 inhibitors in combination cancer therapy? BMC Syst. Biol. 13, 30 (2019).","journal-title":"BMC Syst. Biol."},{"key":"886_CR59","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug. Discov. 3, 391\u2013400 (2004).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"886_CR60","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337 (2021).","journal-title":"Cell"},{"key":"886_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002088","volume":"9","author":"DP Zandberg","year":"2021","unstructured":"Zandberg, D. P. et al. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. J. Immunother. Cancer 9, e002088 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"886_CR62","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1158\/1535-7163.MCT-09-0274","volume":"8","author":"A Rapisarda","year":"2009","unstructured":"Rapisarda, A. et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol. Cancer Ther. 8, 1867\u20131877 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"886_CR63","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911416","volume":"12","author":"L Schito","year":"2020","unstructured":"Schito, L. et al. Metronomic chemotherapy offsets HIF\u03b1 induction upon maximum-tolerated dose in metastatic cancers. EMBO Mol. Med. 12, e11416 (2020).","journal-title":"EMBO Mol. Med."},{"key":"886_CR64","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1073\/pnas.1018866109","volume":"109","author":"SJ Conley","year":"2012","unstructured":"Conley, S. J. et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl Acad. Sci. USA 109, 2784\u20132789 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"886_CR65","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1158\/1078-0432.CCR-05-2816","volume":"12","author":"O Riesterer","year":"2006","unstructured":"Riesterer, O. et al. Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin. Cancer Res. 12, 3518\u20133524 (2006).","journal-title":"Clin. Cancer Res."},{"key":"886_CR66","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2012.64","volume":"9","author":"A Rapisarda","year":"2012","unstructured":"Rapisarda, A. & Melillo, G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat. Rev. Clin. Oncol. 9, 378\u2013390 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"886_CR67","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.1158\/0008-5472.CAN-11-2025","volume":"71","author":"S Matsumoto","year":"2011","unstructured":"Matsumoto, S. et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res. 71, 6350\u20136359 (2011).","journal-title":"Cancer Res."},{"key":"886_CR68","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang, Y. et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl Acad. Sci. USA 109, 17561\u201317566 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"886_CR69","doi-asserted-by":"publisher","first-page":"699478","DOI":"10.3389\/fimmu.2021.699478","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. \u201c\u03b3\u03b4T-cell-IL17A-neutrophil\u201d axis drives immunosuppression and confers breast cancer resistance to high-dose anti-VEGFR2 therapy. Front. Immunol. 12, 699478 (2021).","journal-title":"Front. Immunol."},{"key":"886_CR70","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","volume":"71","author":"K Shigeta","year":"2020","unstructured":"Shigeta, K. et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 71, 1247\u20131261 (2020).","journal-title":"Hepatology"},{"key":"886_CR71","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1158\/1535-7163.MCT-08-0715","volume":"7","author":"J Ma","year":"2008","unstructured":"Ma, J. & Waxman, D. J. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol. Cancer Ther. 7, 3670\u20133684 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"886_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001657","volume":"9","author":"DL Ou","year":"2021","unstructured":"Ou, D. L. et al. Regorafenib enhances antitumor immunity via inhibition of p38 kinase\/Creb1\/Klf4 axis in tumor-associated macrophages. J. Immunother. Cancer 9, e001657 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"886_CR73","unstructured":"Abbott, B. Cancer doctors rethink aggressive treatments: cervical, rectal cancer patients responded as well to less invasive care, studies show. The Wall Street Journal www.wsj.com\/articles\/for-some-cancers-less-treatment-is-a-better-bet-ed94d8ef (2023)."},{"key":"886_CR74","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S0140-6736(21)01240-X","volume":"398","author":"RS Kerbel","year":"2021","unstructured":"Kerbel, R. S. & Andre, N. Commentary: adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Lancet 398, 278\u2013279 (2021).","journal-title":"Lancet"},{"key":"886_CR75","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","volume":"398","author":"YP Chen","year":"2021","unstructured":"Chen, Y. P. et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 398, 303\u2013313 (2021).","journal-title":"Lancet"},{"key":"886_CR76","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA 325, 50\u201358 (2021).","journal-title":"JAMA"},{"key":"886_CR77","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/S1470-2045(19)30617-5","volume":"20","author":"G Bisogno","year":"2019","unstructured":"Bisogno, G. et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 20, 1566\u20131575 (2019).","journal-title":"Lancet Oncol."},{"key":"886_CR78","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.22.01015","volume":"41","author":"VM Patil","year":"2023","unstructured":"Patil, V. M. et al. Low-dose immunotherapy in head and neck cancer: a randomized study. J. Clin. Oncol. 41, 222\u2013232 (2023).","journal-title":"J. Clin. Oncol."},{"key":"886_CR79","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1200\/JCO.22.01711","volume":"41","author":"AP Mitchell","year":"2022","unstructured":"Mitchell, A. P. & Goldstein, D. A. Cost savings and increased access with ultra-low-dose immunotherapy. J. Clin. Oncol. 41, 170\u2013173 (2022).","journal-title":"J. Clin. Oncol."},{"key":"886_CR80","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/cpt.2278","volume":"110","author":"MZ Liao","year":"2021","unstructured":"Liao, M. Z. et al. Model-informed therapeutic dose optimization strategies for antibody-drug conjugates in oncology: what can we learn from US Food and Drug Administration-approved antibody\u2013drug conjugates? Clin. Pharmacol. Ther. 110, 1216\u20131230 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"886_CR81","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1158\/1078-0432.CCR-17-0874","volume":"23","author":"S Ueda","year":"2017","unstructured":"Ueda, S., Saeki, T., Osaki, A., Yamane, T. & Kuji, I. Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: multimodal functional imaging and multiplex cytokine analysis. Clin. Cancer Res. 23, 5769\u20135778 (2017).","journal-title":"Clin. Cancer Res."},{"key":"886_CR82","doi-asserted-by":"publisher","first-page":"21247","DOI":"10.18632\/oncotarget.6918","volume":"7","author":"M Arjaans","year":"2016","unstructured":"Arjaans, M. et al. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget 7, 21247\u201321258 (2016).","journal-title":"Oncotarget"},{"key":"886_CR83","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ijc.28046","volume":"133","author":"S Heskamp","year":"2013","unstructured":"Heskamp, S. et al. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int. J. Cancer 133, 307\u2013314 (2013).","journal-title":"Int. J. Cancer"},{"key":"886_CR84","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/1535-7163.MCT-11-0742-T","volume":"11","author":"CV Pastuskovas","year":"2012","unstructured":"Pastuskovas, C. V. et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol. Cancer Ther. 11, 752\u2013762 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"886_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1593\/neo.131848","volume":"16","author":"M Dobosz","year":"2014","unstructured":"Dobosz, M., Ntziachristos, V., Scheuer, W. & Strobel, S. Multispectral fluorescence ultramicroscopy: three-dimensional visualization and automatic quantification of tumor morphology, drug penetration, and antiangiogenic treatment response. Neoplasia 16, 1\u201313 (2014).","journal-title":"Neoplasia"},{"key":"886_CR86","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1158\/0008-5472.CAN-12-3518","volume":"73","author":"M Arjaans","year":"2013","unstructured":"Arjaans, M. et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res. 73, 3347\u20133355 (2013).","journal-title":"Cancer Res."},{"key":"886_CR87","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1208\/s12248-016-9909-y","volume":"18","author":"VA Thomas","year":"2016","unstructured":"Thomas, V. A. & Balthasar, J. P. Sorafenib decreases tumor exposure to an anti-carcinoembryonic antigen monoclonal antibody in a mouse model of colorectal cancer. AAPS J. 18, 923\u2013932 (2016).","journal-title":"AAPS J."},{"key":"886_CR88","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1080\/15384047.2015.1016664","volume":"16","author":"TK Chung","year":"2015","unstructured":"Chung, T. K., Warram, J., Day, K. E., Hartman, Y. & Rosenthal, E. L. Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. Cancer Biol. Ther. 16, 790\u2013798 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"886_CR89","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00280-019-03971-7","volume":"84","author":"DA Goldstein","year":"2019","unstructured":"Goldstein, D. A. & Ratain, M. J. Alternative dosing regimens for atezolizumab: right dose, wrong frequency. Cancer Chemother. Pharmacol. 84, 1153\u20131155 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"886_CR90","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/19420862.2015.1136043","volume":"8","author":"R Deng","year":"2016","unstructured":"Deng, R. et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. mAbs 8, 593\u2013603 (2016).","journal-title":"mAbs"},{"key":"886_CR91","doi-asserted-by":"publisher","first-page":"1157461","DOI":"10.3389\/fonc.2023.1157461","volume":"13","author":"EE Paulsen","year":"2023","unstructured":"Paulsen, E. E. et al. Impact of microvessel patterns and immune status in NSCLC: a non-angiogenic vasculature is an independent negative prognostic factor in lung adenocarcinoma. Front. Oncol. 13, 1157461 (2023).","journal-title":"Front. Oncol."},{"key":"886_CR92","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc1092","volume":"3","author":"MJ Hendrix","year":"2003","unstructured":"Hendrix, M. J., Seftor, E. A., Hess, A. R. & Seftor, R. E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 3, 411\u2013421 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"886_CR93","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3389\/fonc.2020.01140","volume":"10","author":"C L\u00f3pez-Camarillo","year":"2020","unstructured":"L\u00f3pez-Camarillo, C., Ruiz-Garc\u00eda, E., Starling, N. & Marchat, L. A. Editorial: neovascularization, angiogenesis and vasculogenic mimicry in cancer. Front. Oncol. 10, 1140 (2020).","journal-title":"Front. Oncol."},{"key":"886_CR94","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1161\/ATVBAHA.118.312190","volume":"39","author":"Z Ali","year":"2019","unstructured":"Ali, Z. et al. Intussusceptive vascular remodeling precedes pathological neovascularization. Arterioscler. Thromb. Vasc. Biol. 39, 1402\u20131418 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"886_CR95","first-page":"1417","volume":"151","author":"F Pezzella","year":"1997","unstructured":"Pezzella, F. et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 151, 1417\u20131423 (1997).","journal-title":"Am. J. Pathol."},{"key":"886_CR96","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41571-019-0181-9","volume":"16","author":"EA Kuczynski","year":"2019","unstructured":"Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S. & Reynolds, A. R. Vessel co-option in cancer. Nat. Rev. Clin. Oncol. 16, 469\u2013493 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"886_CR97","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/path.4845","volume":"241","author":"VL Bridgeman","year":"2016","unstructured":"Bridgeman, V. L. et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J. Pathol. 241, 362\u2013374 (2016).","journal-title":"J. Pathol."},{"key":"886_CR98","doi-asserted-by":"publisher","first-page":"965277","DOI":"10.3389\/fonc.2022.965277","volume":"12","author":"A Cuypers","year":"2022","unstructured":"Cuypers, A., Truong, A. K., Becker, L. M., Saavedra-Garc\u00eda, P. & Carmeliet, P. Tumor vessel co-option: the past & the future. Front. Oncol. 12, 965277 (2022).","journal-title":"Front. Oncol."},{"key":"886_CR99","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrc.2018.14","volume":"18","author":"T Donnem","year":"2018","unstructured":"Donnem, T. et al. Non-angiogenic tumours and their influence on cancer biology. Nat. Rev. Cancer 18, 323\u2013336 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"886_CR100","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/path.966","volume":"195","author":"PB Vermeulen","year":"2001","unstructured":"Vermeulen, P. B. et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J. Pathol. 195, 336\u2013342 (2001).","journal-title":"J. Pathol."},{"key":"886_CR101","first-page":"341","volume":"62","author":"B Kusters","year":"2002","unstructured":"Kusters, B. et al. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 62, 341\u2013345 (2002).","journal-title":"Cancer Res."},{"key":"886_CR102","doi-asserted-by":"publisher","first-page":"874554","DOI":"10.3389\/fonc.2022.874554","volume":"12","author":"D Ribatti","year":"2022","unstructured":"Ribatti, D. & Pezzella, F. Vascular co-option and other alternative modalities of growth of tumor vasculature in glioblastoma. Front. Oncol. 12, 874554 (2022).","journal-title":"Front. Oncol."},{"key":"886_CR103","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semcancer.2018.01.009","volume":"52","author":"PJ van Dam","year":"2018","unstructured":"van Dam, P. J. et al. Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy. Semin. Cancer Biol. 52, 86\u201393 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"886_CR104","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41416-020-0881-z","volume":"123","author":"DJ H\u00f6ppener","year":"2020","unstructured":"H\u00f6ppener, D. J. et al. Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis. Br. J. Cancer 123, 196\u2013206 (2020).","journal-title":"Br. J. Cancer"},{"key":"886_CR105","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/nm.4197","volume":"22","author":"S Frentzas","year":"2016","unstructured":"Frentzas, S. et al. Vessel co-option mediates resistance to antiangiogenic therapy in liver metastases. Nat. Med. 22, 1294\u20131302 (2016).","journal-title":"Nat. Med."},{"key":"886_CR106","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1158\/0008-5472.CAN-12-4183","volume":"73","author":"E Guerin","year":"2013","unstructured":"Guerin, E., Man, S., Xu, P. & Kerbel, R. S. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res. 73, 2743\u20132748 (2013).","journal-title":"Cancer Res."},{"key":"886_CR107","doi-asserted-by":"publisher","first-page":"101691","DOI":"10.1016\/j.xpro.2022.101691","volume":"3","author":"A Cuypers","year":"2022","unstructured":"Cuypers, A. et al. Generation of vessel co-option lung metastases mouse models for single-cell isolation of metastases-derived cells and endothelial cells. Star. Protoc. 3, 101691 (2022).","journal-title":"Star. Protoc."},{"key":"886_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109253","volume":"35","author":"LA Teuwen","year":"2021","unstructured":"Teuwen, L. A. et al. Tumor vessel co-option probed by single-cell analysis. Cell Rep. 35, 109253 (2021).","journal-title":"Cell Rep."},{"key":"886_CR109","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"N. Engl. J. Med."},{"key":"886_CR110","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289\u20131300 (2021).","journal-title":"N. Engl. J. Med."},{"key":"886_CR111","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","volume":"24","author":"TK Choueiri","year":"2023","unstructured":"Choueiri, T. K. et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 24, 228\u2013238 (2023).","journal-title":"Lancet Oncol."},{"key":"886_CR112","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829\u2013841 (2021).","journal-title":"N. Engl. J. Med."},{"key":"886_CR113","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393, 2404\u20132415 (2019).","journal-title":"Lancet"},{"key":"886_CR114","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"886_CR115","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 22, 977\u2013990 (2021).","journal-title":"Lancet Oncol."},{"key":"886_CR116","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 402, 1133\u20131146 (2023).","journal-title":"Lancet"},{"key":"886_CR117","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103\u20131115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"886_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100450","volume":"7","author":"Y Tomita","year":"2022","unstructured":"Tomita, Y. et al. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101. ESMO open. 7, 100450 (2022).","journal-title":"ESMO open."},{"key":"886_CR119","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","volume":"23","author":"RK Kelley","year":"2022","unstructured":"Kelley, R. K. et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 23, 995\u20131008 (2022).","journal-title":"Lancet Oncol."},{"key":"886_CR120","doi-asserted-by":"publisher","first-page":"S1401","DOI":"10.1016\/j.annonc.2022.08.031","volume":"33","author":"RS Finn","year":"2022","unstructured":"Finn, R. S. et al. Primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) [abstract LBA34]. Ann. Oncol. 33, S1401 (2022).","journal-title":"Ann. Oncol."},{"key":"886_CR121","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore, K. N. et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J. Clin. Oncol. 39, 1842\u20131855 (2021).","journal-title":"J. Clin. Oncol."},{"key":"886_CR122","unstructured":"Merck. Merck and Eisai provide update on two phase 3 trials evaluating KEYTRUDA\u00ae (pembrolizumab) plus LENVIMA\u00ae (lenvatinib) in patients with certain types of metastatic non-small cell lung cancer. Merck www.merck.com\/news\/merck-and-eisai-provide-update-on-two-phase-3-trials-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-patients-with-certain-types-of-metastatic-non-small-cell-lung-cancer\/ (2023)."},{"key":"886_CR123","doi-asserted-by":"publisher","first-page":"S1429","DOI":"10.1016\/j.annonc.2021.10.139","volume":"32","author":"JCH Yang","year":"2021","unstructured":"Yang, J. C. H. et al. Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS\u22651% (LEAP-007): a phase III, randomized, double-blind study [abstract 120O]. Ann. Oncol. 32, S1429\u2013S1430 (2021).","journal-title":"Ann. Oncol."},{"issue":"6 Suppl.","key":"886_CR124","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1200\/JCO.2022.40.6_suppl.432","volume":"40","author":"Y Loriot","year":"2022","unstructured":"Loriot, Y. et al. First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): a phase 3, randomized, double-blind study [abstract]. J. Clin. Oncol. 40 (Suppl. 6), 432 (2022).","journal-title":"J. Clin. Oncol."},{"key":"886_CR125","unstructured":"Merck. Merck and Eisai provide update on phase 3 LEAP-010 trial evaluating KEYTRUDA\u00ae (pembrolizumab) plus LENVIMA\u00ae (lenvatinib) in patients with certain types of recurrent or metastatic head and neck squamous cell carcinoma. Merck www.merck.com\/news\/merck-and-eisai-provide-update-on-phase-3-leap-010-trial-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-patients-with-certain-types-of-recurrent-or-metastatic-head-and-ne\/ (2023)."},{"key":"886_CR126","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker, V. et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N. Engl. J. Med. 386, 437\u2013448 (2022).","journal-title":"N. Engl. J. Med."},{"key":"886_CR127","unstructured":"Merck. Merck and Eisai provide update on phase 3 LEAP-001 trial evaluating KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) as first-line treatment for patients with advanced or recurrent endometrial carcinoma. Merck www.merck.com\/news\/merck-and-eisai-provide-update-on-phase-3-leap-001-trial-evaluating-pembrolizumab-plus-lenvima-lenvatinib-as-first-line-treatment-for-patients-with-advanced-or-recurrent-endometrial-carcinom\/ (2023)."},{"key":"886_CR128","unstructured":"Ipsen. Exelixis and Ipsen announce positive results from phase 3 CONTACT-02 pivotal trial evaluating cabozantinib in combination with atezolizumab in metastatic castration-resistant prostate cancer. Ipsen www.ipsen.com\/press-releases\/exelixis-and-ipsen-announce-positive-results-from-phase-3-contact-02-pivotal-trial-evaluating-cabozantinib-in-combination-with-atezolizumab-in-metastatic-castration-resistant-prostate-cancer\/ (2023)."},{"key":"886_CR129","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/jnci\/djp177","volume":"101","author":"T Fojo","year":"2009","unstructured":"Fojo, T. & Grady, C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 101, 1044\u20131048 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"886_CR130","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.1158\/1078-0432.CCR-16-3065","volume":"23","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou, V. et al. Immuno-oncology trial endpoints: capturing clinically meaningful activity. Clin. Cancer Res. 23, 4959\u20134969 (2017).","journal-title":"Clin. Cancer Res."},{"key":"886_CR131","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157347","volume":"8","author":"TT Tran","year":"2023","unstructured":"Tran, T. T. et al. Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma. JCI insight 8, e157347 (2023).","journal-title":"JCI insight"},{"key":"886_CR132","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.20.02363","volume":"39","author":"DF McDermott","year":"2021","unstructured":"McDermott, D. F. et al. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma. J. Clin. Oncol. 39, 1020\u20131028 (2021).","journal-title":"J. Clin. Oncol."},{"key":"886_CR133","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1158\/1078-0432.CCR-21-3807","volume":"28","author":"G Verset","year":"2022","unstructured":"Verset, G. et al. Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase II KEYNOTE-224 trial. Clin. Cancer Res. 28, 2547\u20132554 (2022).","journal-title":"Clin. Cancer Res."},{"key":"886_CR134","doi-asserted-by":"publisher","first-page":"Jco2300529","DOI":"10.1200\/JCO.23.00529","volume":"41","author":"JE Kurtz","year":"2023","unstructured":"Kurtz, J. E. et al. Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial. J. Clin. Oncol. 41, Jco2300529 (2023).","journal-title":"J. Clin. Oncol."},{"key":"886_CR135","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med."},{"key":"886_CR136","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003027","volume":"10","author":"HJ West","year":"2022","unstructured":"West, H. J. et al. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. J. Immunother. Cancer 10, e003027 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"886_CR137","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.49040","volume":"5","author":"NB Mettu","year":"2022","unstructured":"Mettu, N. B. et al. Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial. JAMA Netw. Open. 5, e2149040 (2022).","journal-title":"JAMA Netw. Open."},{"key":"886_CR138","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka, S. et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38, 2053\u20132061 (2020).","journal-title":"J. Clin. Oncol."},{"key":"886_CR139","doi-asserted-by":"publisher","first-page":"101917","DOI":"10.1016\/j.eclinm.2023.101917","volume":"58","author":"M Fakih","year":"2023","unstructured":"Fakih, M. et al. Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine 58, 101917 (2023).","journal-title":"EClinicalMedicine"},{"key":"886_CR140","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1158\/1078-0432.CCR-22-0630","volume":"28","author":"H Yukami","year":"2022","unstructured":"Yukami, H. et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin. Cancer Res. 28, 3480\u20133488 (2022).","journal-title":"Clin. Cancer Res."},{"key":"886_CR141","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","volume":"403","author":"A Oaknin","year":"2024","unstructured":"Oaknin, A. et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet 403, 31\u201343 (2024).","journal-title":"Lancet"},{"key":"886_CR142","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749\u2013757 (2018).","journal-title":"Nat. Med."},{"key":"886_CR143","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1200\/JCO.21.02938","volume":"40","author":"MB Atkins","year":"2022","unstructured":"Atkins, M. B. et al. Phase II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). J. Clin. Oncol. 40, 2913\u20132923 (2022).","journal-title":"J. Clin. Oncol."},{"key":"886_CR144","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","volume":"6","author":"J Duan","year":"2020","unstructured":"Duan, J. et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 6, 375\u2013384 (2020).","journal-title":"JAMA Oncol."},{"key":"886_CR145","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862\u2013873 (2022).","journal-title":"J. Hepatol."},{"key":"886_CR146","unstructured":"Merck. Merck and Eisai provide update on phase 3 trials of KEYTRUDA\u00ae (pembrolizumab) plus LENVIMA\u00ae (lenvatinib) in certain patients with advanced melanoma (LEAP-003) and metastatic colorectal cancer (LEAP-017). Merck www.merck.com\/news\/merck-and-eisai-provide-update-on-phase-3-trials-of-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-certain-patients-with-advanced-melanoma-leap-003-and-metastatic-colorectal-cance\/ (2023)."},{"key":"886_CR147","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/S1556-0864(23)00260-5","volume":"18","author":"J Neal","year":"2023","unstructured":"Neal, J. et al. CONTACT-01: efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy [abstact 60]. J. Thorac. Oncol. 18, S39\u2013S40 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"886_CR148","unstructured":"Mirati Therapeutics. Mirati Therapeutics provides update on the phase 3 SAPPHIRE study evaluating sitravatinib in combination with OPDIVO\u00ae. PR Newswire www.prnewswire.com\/news-releases\/mirati-therapeutics-provides-update-on-the-phase-3-sapphire-study-evaluating-sitravatinib-in-combination-with-opdivo-301833958.html (2023)."},{"key":"886_CR149","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal, S. K. et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 402, 185\u2013195 (2023).","journal-title":"Lancet"},{"key":"886_CR150","doi-asserted-by":"publisher","first-page":"107173","DOI":"10.1016\/j.lungcan.2023.03.009","volume":"179","author":"M Reck","year":"2023","unstructured":"Reck, M. et al. Anti-angiogenic agents for NSCLC following first-line immunotherapy: rationale, recent updates, and future perspectives. Lung Cancer 179, 107173 (2023).","journal-title":"Lung Cancer"},{"key":"886_CR151","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch, E. et al. Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease. N. Engl. J. Med. 385, 2036\u20132046 (2021).","journal-title":"N. Engl. J. Med."},{"key":"886_CR152","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1200\/JCO.2023.41.16_suppl.2008","volume":"41","author":"O Iliopoulos","year":"2023","unstructured":"Iliopoulos, O. et al. Belzutifan treatment for von Hippel\u2013Lindau (VHL) disease-associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study [abstract]. J. Clin. Oncol. 41, 2008 (2023).","journal-title":"J. Clin. Oncol."},{"key":"886_CR153","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1200\/JCO.2023.41.16_suppl.4553","volume":"41","author":"L Albiges","year":"2023","unstructured":"Albiges, L. et al. Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1\/L1 and VEGF inhibitor: preliminary results of arm B5 of the phase 1\/2 KEYMAKER-U03B study [abstract]. J. Clin. Oncol. 41, 4553 (2023).","journal-title":"J. Clin. Oncol."},{"key":"886_CR154","doi-asserted-by":"publisher","first-page":"S1329","DOI":"10.1016\/j.annonc.2023.10.090","volume":"34","author":"L Albiges","year":"2023","unstructured":"Albiges, L. et al. Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase III LITESPARK-005 study [abstract LBA88]. Ann. Oncol. 34, S1329\u2013S1330 (2023).","journal-title":"Ann. Oncol."},{"key":"886_CR155","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","volume":"24","author":"TK Choueiri","year":"2023","unstructured":"Choueiri, T. K. et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. 24, 553\u2013562 (2023).","journal-title":"Lancet Oncol."},{"key":"886_CR156","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"886_CR157","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10549-015-3410-7","volume":"151","author":"LV Santos","year":"2015","unstructured":"Santos, L. V., Cruz, M. R., Lopes Gde, L. & Lima, J. P. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res. Treat. 151, 481\u2013489 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"886_CR158","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten, T. F. et al. Biomarkers for immunotherapy of hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 20, 780\u2013798 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"886_CR159","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28, 1599\u20131611 (2022).","journal-title":"Nat. Med."},{"key":"886_CR160","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","volume":"20","author":"M Rosellini","year":"2023","unstructured":"Rosellini, M. et al. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat. Rev. Urol. 20, 133\u2013157 (2023).","journal-title":"Nat. Rev. Urol."},{"key":"886_CR161","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/imr.12522","volume":"276","author":"YT Akalu","year":"2017","unstructured":"Akalu, Y. T., Rothlin, C. V. & Ghosh, S. TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol. Rev. 276, 165\u2013177 (2017).","journal-title":"Immunol. Rev."},{"key":"886_CR162","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.4049\/jimmunol.175.4.2301","volume":"175","author":"V Vargas-Leal","year":"2005","unstructured":"Vargas-Leal, V. et al. Expression and function of glial cell line-derived neurotrophic factor family ligands and their receptors on human immune cells. J. Immunol. 175, 2301\u20132308 (2005).","journal-title":"J. Immunol."},{"key":"886_CR163","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14144","volume":"6","author":"BA Maiorano","year":"2023","unstructured":"Maiorano, B. A., Ciardiello, D., Maiello, E. & Roviello, G. Comparison of anti-programmed cell death ligand 1 therapy combinations vs sunitinib for metastatic renal cell carcinoma: a meta-analysis. JAMA Netw. Open. 6, e2314144 (2023).","journal-title":"JAMA Netw. Open."},{"key":"886_CR164","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1001\/jamaoncol.2022.4733","volume":"8","author":"C Kim","year":"2022","unstructured":"Kim, C. et al. Association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma. JAMA Oncol. 8, 1825\u20131829 (2022).","journal-title":"JAMA Oncol."},{"key":"886_CR165","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","volume":"544","author":"L Tian","year":"2017","unstructured":"Tian, L. et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544, 250\u2013254 (2017).","journal-title":"Nature"},{"key":"886_CR166","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1172\/JCI96582","volume":"128","author":"X Zheng","year":"2018","unstructured":"Zheng, X. et al. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J. Clin. Invest. 128, 2104\u20132115 (2018).","journal-title":"J. Clin. Invest."},{"key":"886_CR167","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature22311","volume":"545","author":"T Kammertoens","year":"2017","unstructured":"Kammertoens, T. et al. Tumour ischaemia by interferon-\u03b3 resembles physiological blood vessel regression. Nature 545, 98\u2013102 (2017).","journal-title":"Nature"},{"key":"886_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2511-3","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu, S. et al. Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 11, 309 (2020).","journal-title":"Cell Death Dis."},{"key":"886_CR169","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.22.00912","volume":"40","author":"KL Reckamp","year":"2022","unstructured":"Reckamp, K. L. et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A. J. Clin. Oncol. 40, 2295\u20132306 (2022).","journal-title":"J. Clin. Oncol."},{"key":"886_CR170","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1093\/annonc\/mdx414","volume":"28","author":"CE McCoach","year":"2017","unstructured":"McCoach, C. E. et al. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann. Oncol. 28, 2707\u20132714 (2017).","journal-title":"Ann. Oncol."},{"key":"886_CR171","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2014.12.036","volume":"67","author":"V Gr\u00fcnwald","year":"2015","unstructured":"Gr\u00fcnwald, V. et al. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur. Urol. 67, 952\u2013958 (2015).","journal-title":"Eur. Urol."},{"key":"886_CR172","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.ejca.2015.06.116","volume":"51","author":"V Heinemann","year":"2015","unstructured":"Heinemann, V. et al. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur. J. Cancer 51, 1927\u20131936 (2015).","journal-title":"Eur. J. Cancer"},{"key":"886_CR173","doi-asserted-by":"publisher","first-page":"1230731","DOI":"10.3389\/fonc.2023.1230731","volume":"13","author":"K Saijo","year":"2023","unstructured":"Saijo, K. et al. Depth of response may predict clinical outcome in patients with recurrent\/metastatic head and neck cancer treated with pembrolizumab-containing regimens. Front. Oncol. 13, 1230731 (2023).","journal-title":"Front. Oncol."},{"key":"886_CR174","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D. et al. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"886_CR175","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau, T. et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 6, e204564 (2020).","journal-title":"JAMA Oncol."},{"key":"886_CR176","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079","volume":"5","author":"L Albiges","year":"2020","unstructured":"Albiges, L. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 5, e001079 (2020).","journal-title":"ESMO Open"},{"key":"886_CR177","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1200\/JCO.22.00972","volume":"41","author":"T Yau","year":"2023","unstructured":"Yau, T. et al. Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the CheckMate 040 trial. J. Clin. Oncol. 41, 1747\u20131757 (2023).","journal-title":"J. Clin. Oncol."},{"key":"886_CR178","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.dld.2023.01.161","volume":"55","author":"P Merle","year":"2023","unstructured":"Merle, P. et al. Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial. Dig. Liver Dis. 55, 464\u2013470 (2023).","journal-title":"Dig. Liver Dis."},{"key":"886_CR179","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","volume":"388","author":"TK Choueiri","year":"2023","unstructured":"Choueiri, T. K. et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N. Engl. J. Med. 388, 1767\u20131778 (2023).","journal-title":"N. Engl. J. Med."},{"key":"886_CR180","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1200\/JCO.21.01806","volume":"40","author":"BI Rini","year":"2022","unstructured":"Rini, B. I. et al. Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN Renal 101 trial. J. Clin. Oncol. 40, 1929\u20131938 (2022).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00886-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00886-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00886-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T09:01:37Z","timestamp":1716541297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00886-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":180,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["886"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00886-y","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"18 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S.K. has received research funding from Genentech and Novelty Nobility, and is a consultant for Novelty Nobility, OncoHost and PharmAbcine. H.-Y.K. and K.A.K. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}